Everest Organics Ltd
Everest Organics Ltd Live Price Chart
Everest Organics Ltd Technicals
| 20 Day | ₹ 428.797 |
| 50 Day | ₹ 439.400 |
| 100 Day | ₹ 426.669 |
| 200 Day | ₹ 389.232 |
| 20 Day | ₹ 436.725 |
| 50 Day | ₹ 451.898 |
| 100 Day | ₹ 429.305 |
| 200 Day | ₹ 401.945 |
Everest Organics Ltd Performance
| Previous Close | ₹ 415.05 |
| High | ₹ 430 |
| Volume | 306 |
| 52W Range | ₹ 210.95 - ₹ 536.4 |
| Open | ₹ 415.05 |
| Low | ₹ 404 |
| Market Cap | ₹ 400 Cr |
Everest Organics Ltd Fundamentals
| ROCE | 9.865 |
| P/E Ratio | 60.950 |
| P/B Ratio | 5.560 |
| Industry P/E | 5.560 |
| Debt to Equity | 39.828 |
| ROE | 9.122 |
| EPS | 6.810 |
| Dividend Yield | 0.000 |
| Book Value | 74.669 |
| Face Value | 10.000 |
Everest Organics Ltd Financials
| Particulars | Y202503 | Y202403 | Y202303 | Y202203 | Y202103 |
|---|---|---|---|---|---|
| Total Revenue | 160.1659 | 198.1274 | 189.992 | 202.2579 | 182.6286 |
| Total Expenses | 163.4084 | 197.517 | 189.9021 | 200.5186 | 165.355 |
| Profit After Tax | -1.2903 | 0.1392 | -0.1822 | 1.1437 | 13.715 |
Everest Organics Ltd Shareholding Pattern
| Promoter Holdings | 59.609 % |
| FIIs | 0.000 % |
| DIIs | 0.023 % |
| MutualFund | 0.000 % |
| Retail | 26.104 % |
| Others - | 14.264 % |
About Everest Organics Ltd
History of Everest Organics Ltd
Everest Organics Limited was incorporated at Hyderabad in February, 1993. It was promoted by S K Srihari Raju and S K. Chittiramabhadra Raju. The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediaries. The Company commenced its commercial operations in the year 1993. It set up a plant at Aroor, Andhra Pradesh to manufacture bulk drugs and formulations. It came out with a public issue in Jan.'95 to part-finance the project. Commercial production of ciprofloxacin and omerprazole commenced in Feb.'96. The company preferred to manufacture para hydroxy phynyl glycin (PHPG), but due to market conditions, it decided to drop manufacturing of PHPG and has decided to enhance the capacity of ciprofloxacin from 30 tpa to 120 tpa and also to manufacture enrofloxacin/naproxen. It introduced one more new product by name Esomeprazole Magnesium by creating additional facility by making investment in plant & machinery in 2007-08. In 2024-25, the Company increased its installed capacity of Benzimidazole by 60 tpa there by taking its capacity to 120 tpa. The installed capacity of Omeprazole Op Sulphide has been increased from 15 TPA to 30 TPA in FY 2025. ...
